319 related articles for article (PubMed ID: 36933003)
41. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population.
Kumar N; Das V; Agarwal A; Agrawal S
AJOG Glob Rep; 2023 May; 3(2):100177. PubMed ID: 36911235
[TBL] [Abstract][Full Text] [Related]
42. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
Ren Z; Cui N; Zhu M; Khalil RA
Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955
[TBL] [Abstract][Full Text] [Related]
43. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
[TBL] [Abstract][Full Text] [Related]
44. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
45. Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam.
Nguyen TH; Bui TC; Vo TM; Tran QM; Luu LT; Nguyen TD
Pregnancy Hypertens; 2018 Oct; 14():37-42. PubMed ID: 30527116
[TBL] [Abstract][Full Text] [Related]
46. Circulating angiogenic profiles and histo-morphological placental characteristics of uncomplicated post-date pregnancies.
Mitlid-Mork B; Turowski G; Bowe S; Staff AC; Sugulle M
Placenta; 2021 Jun; 109():55-63. PubMed ID: 33990027
[TBL] [Abstract][Full Text] [Related]
47. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia.
Rana S; Hacker MR; Modest AM; Salahuddin S; Lim KH; Verlohren S; Perschel FH; Karumanchi SA
Hypertension; 2012 Aug; 60(2):451-8. PubMed ID: 22753210
[TBL] [Abstract][Full Text] [Related]
48. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
[TBL] [Abstract][Full Text] [Related]
49. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
[TBL] [Abstract][Full Text] [Related]
50. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
[TBL] [Abstract][Full Text] [Related]
51. Soluble fms-like tyrosine kinase-1, placental growth factor and their ratio as a predictor for pre-eclampsia in East Asians.
Cheng YKY; Law LW; Leung TY; Chan OK; Sahota DS
Pregnancy Hypertens; 2018 Jan; 11():61-65. PubMed ID: 29523275
[TBL] [Abstract][Full Text] [Related]
52. Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY; Wright D; Koutoulas L; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Feb; 49(2):201-208. PubMed ID: 27671370
[TBL] [Abstract][Full Text] [Related]
53. Fetal cardiac function at 35-37 weeks' gestation in pregnancies that subsequently develop pre-eclampsia.
Semmler J; Garcia-Gonzalez C; Sanchez Sierra A; Gallardo Arozena M; Nicolaides KH; Charakida M
Ultrasound Obstet Gynecol; 2021 Mar; 57(3):417-422. PubMed ID: 33098138
[TBL] [Abstract][Full Text] [Related]
54. sFlt-1/PlGF Ratio at 24 Weeks Gestation in Twin Pregnancies as a Predictor of Preeclampsia or Fetal Growth Restriction.
Martínez-Varea A; Martínez-Sáez C; Domenech J; Desco-Blay J; Monfort-Pitarch S; Hueso M; Diago-Almela V
Fetal Diagn Ther; 2022; 49(4):206-214. PubMed ID: 35609518
[TBL] [Abstract][Full Text] [Related]
55. Maternal circulating angiogenic factors in twin and singleton pregnancies.
Faupel-Badger JM; McElrath TF; Lauria M; Houghton LC; Lim KH; Parry S; Cantonwine D; Lai G; Karumanchi SA; Hoover RN; Troisi R
Am J Obstet Gynecol; 2015 May; 212(5):636.e1-8. PubMed ID: 25434840
[TBL] [Abstract][Full Text] [Related]
56. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.
Shibata E; Rajakumar A; Powers RW; Larkin RW; Gilmour C; Bodnar LM; Crombleholme WR; Ness RB; Roberts JM; Hubel CA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4895-903. PubMed ID: 15886253
[TBL] [Abstract][Full Text] [Related]
57. Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population.
Kienast C; Moya W; Rodriguez O; Jijón A; Geipel A
J Matern Fetal Neonatal Med; 2016; 29(4):537-43. PubMed ID: 25708492
[TBL] [Abstract][Full Text] [Related]
58. Course of the sFlt-1/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery.
Andrikos A; Andrikos D; Schmidt B; Birdir C; Kimmig R; Gellhaus A; Köninger A
Arch Gynecol Obstet; 2022 Mar; 305(3):597-605. PubMed ID: 34432111
[TBL] [Abstract][Full Text] [Related]
59. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: A case-control study.
Simón E; Herraiz I; Villalaín C; Gómez-Arriaga PI; Quezada MS; López-Jiménez EA; Galindo A
Pregnancy Hypertens; 2020 Apr; 20():44-49. PubMed ID: 32172169
[TBL] [Abstract][Full Text] [Related]
60. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
